Currently, people with type 2 diabetes are increasingly prescribed with newly introduced oral glucose‐lowering agents, such as sodium glucose co‐transporter 2 inhibitors (SGLT2 Is), glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) or dipeptidyl peptidase‐4 inhibitors (DPP4 Is). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.